Companies
Creative Biolabs
Services
Conjugate Sites Analysis

Conjugate Sites Analysis

Antibody-drug conjugates employ the specific monoclonal antibodies (mAbs) to achieve targeted delivery of the conjugated cytotoxic molecules to tumor cells. This delicate design increases the payload efficacy against tumor cells and in the meantime, reduces the cytotoxicity of the otherwise highly toxic payload to normal tissues comparing to traditional chemotherapeutic treatments. However, the ADCs are more complex and heterogeneous compared to the unmodified therapeutic mAbs. This is mainly due to a wide distribution of drug conjugation sites, the unique characteristics of the conjugation sites, and different types of conjugation chemistries. As a result, the effects of ADCs are remarkably different. https://www.creative-biolabs.com/adc/conjugate-sites-analysis.htm